Total Payments
$217,662
2024 Payments
$6,334
Companies
6
Transactions
223
Medicare Patients
1,600
Medicare Billing
$230,046
Payment Breakdown by Category
Other$156,618 (72.0%)
Consulting$26,995 (12.4%)
Travel$26,658 (12.2%)
Food & Beverage$5,824 (2.7%)
Research$1,567 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $156,618 | 57 | 72.0% |
| Consulting Fee | $26,995 | 7 | 12.4% |
| Travel and Lodging | $26,658 | 61 | 12.2% |
| Food and Beverage | $5,824 | 86 | 2.7% |
| Unspecified | $1,567 | 12 | 0.7% |
Payments by Type
General
$216,095
211 transactions
Research
$1,567
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $171,367 | 169 | $0 (2024) |
| Genentech USA, Inc. | $34,669 | 31 | $0 (2022) |
| F. Hoffmann-La Roche AG | $9,271 | 8 | $0 (2019) |
| United Therapeutics Corporation | $1,567 | 12 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $722.82 | 2 | $0 (2020) |
| Celgene Corporation | $65.46 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,334 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($4,767) |
| 2023 | $20,507 | 15 | Boehringer Ingelheim Pharmaceuticals, Inc. ($20,507) |
| 2022 | $6,241 | 9 | Boehringer Ingelheim Pharmaceuticals, Inc. ($6,104) |
| 2021 | $18,435 | 10 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18,435) |
| 2020 | $21,178 | 16 | Boehringer Ingelheim Pharmaceuticals, Inc. ($16,159) |
| 2019 | $40,964 | 34 | Genentech USA, Inc. ($23,262) |
| 2018 | $67,648 | 65 | Boehringer Ingelheim Pharmaceuticals, Inc. ($60,634) |
| 2017 | $36,354 | 59 | Boehringer Ingelheim Pharmaceuticals, Inc. ($29,476) |
All Payment Transactions
223 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 07/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $758.10 | General |
| 07/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $108.52 | General |
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $50.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $40.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $25.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $12.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/26/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $11.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $778.34 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $234.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $206.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | In-kind items and services | $125.00 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 01/25/2024 | United Therapeutics Corporation | TYVASO (Drug) | — | Cash or cash equivalent | $11.05 | Research |
| Study: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) • Category: Progressive Pulmonary Fibrosis | ||||||
| 12/05/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 11/21/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,800.00 | General |
| 11/14/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $126.64 | General |
| Category: RESPIRATORY | ||||||
| 11/08/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 10/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $758.10 | General |
| 10/10/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $92.05 | General |
| 10/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $959.50 | General |
| 10/03/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $117.98 | General |
| 04/20/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $54.96 | General |
| 02/26/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Travel and Lodging | In-kind items and services | $603.55 | General |
| Category: RESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF) | United Therapeutics Corporation | $1,567 | 12 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 332 | 467 | $203,619 | $37,637 |
| 2022 | 9 | 426 | 830 | $311,995 | $67,108 |
| 2021 | 10 | 395 | 769 | $284,686 | $62,419 |
| 2020 | 9 | 447 | 875 | $309,420 | $62,882 |
Total Patients
1,600
Total Services
2,941
Medicare Billing
$230,046
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 129 | 180 | $62,066 | $17,114 | 27.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 24 | 80 | $20,000 | $7,304 | 36.5% |
| 31628 | Biopsy of lobe of lung using an endoscope, 1 lobe | Facility | 2023 | 36 | 45 | $47,565 | $5,891 | 12.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 23 | 23 | $11,270 | $2,762 | 24.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 26 | 26 | $7,072 | $2,257 | 31.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 18 | $4,590 | $1,212 | 26.4% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 42 | 51 | $42,432 | $684.88 | 1.6% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 36 | 44 | $8,624 | $413.60 | 4.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 66 | 396 | $99,000 | $31,140 | 31.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 134 | 177 | $60,888 | $16,831 | 27.6% |
| 31628 | Biopsy of lobe of lung using an endoscope, 1 lobe | Facility | 2022 | 40 | 50 | $52,850 | $6,038 | 11.4% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 30 | $14,577 | $4,719 | 32.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 33 | 33 | $16,216 | $3,977 | 24.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 24 | 25 | $6,800 | $1,966 | 28.9% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $3,608 | $1,188 | 32.9% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 48 | 58 | $48,256 | $811.33 | 1.7% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 40 | 50 | $9,800 | $438.34 | 4.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 54 | 349 | $87,250 | $25,328 | 29.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 135 | 187 | $64,328 | $18,804 | 29.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 39 | 39 | $19,110 | $5,534 | 29.0% |
| 31628 | Biopsy of one lobe of lung using an endoscope | Facility | 2021 | 35 | 43 | $45,451 | $5,458 | 12.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $6,318 | $2,295 | 36.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 20 | 20 | $5,440 | $1,772 | 32.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 14 | 14 | $4,592 | $1,574 | 34.3% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2021 | 40 | 49 | $40,768 | $710.18 | 1.7% |
About Dr. Lake Morrison, MD
Dr. Lake Morrison, MD is a Critical Care Medicine healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992739619.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lake Morrison, MD has received a total of $217,662 in payments from pharmaceutical and medical device companies, with $6,334 received in 2024. These payments were reported across 223 transactions from 6 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($156,618).
As a Medicare-enrolled provider, Morrison has provided services to 1,600 Medicare beneficiaries, totaling 2,941 services with total Medicare billing of $230,046. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Durham, NC
- Active Since 07/10/2006
- Last Updated 08/16/2013
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1992739619
Products in Payments
- OFEV (Drug) $11,132
- Esbriet (Biological) $9,473
- TYVASO (Drug) $1,567
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Critical Care Medicine Doctors in Durham
Neil Macintyre, M.d, M.D
Critical Care Medicine — Payments: $158,298
Critical Care Medicine $158,298
Yuh-Chin Huang, Md, MD
Critical Care Medicine — Payments: $16,825
Critical Care Medicine $16,825
David Shaz, Md, MD
Critical Care Medicine — Payments: $9,663
Critical Care Medicine $9,663
Adjoa Evans, Md, MD
Critical Care Medicine — Payments: $758.00
Critical Care Medicine $758.00
Marcos Rosado, M.d, M.D
Critical Care Medicine — Payments: $640.39
Critical Care Medicine $640.39
Dwayne Bell, Acnp, ACNP
Critical Care Medicine — Payments: $600.00
Critical Care Medicine $600.00